MR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Mindray Medical International Ltd's research and development for the three months ended in Mar. 2014 was $30 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2014 was $131 Mil.
This is the expense the company spent on research and development.
Mindray Medical International Ltd Research & Development for the trailing twelve months (TTM) ended in Mar. 2014 was 28.573 (Jun. 2013 ) + 31.573 (Sep. 2013 ) + 40.99 (Dec. 2013 ) + 30.143 (Mar. 2014 ) = $131 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Mindray Medical International Ltd Annual Data
|Research & Development||7||13||19||30||59||58||60||82||104||127|
Mindray Medical International Ltd Quarterly Data
|Research & Development||26||24||24||23||33||26||29||32||41||30|